World Alzheimer’s Day 2022

An estimated 50 million people around the world currently live with Alzheimer's disease or other dementias, dementia being a collective term for progressive syndromes that affect various expressions of cognitive function, such as memory and emotional expression. Alzheimer’s disease accounts for the majority of cases (50 to 70%, varying by country, based on Alzheimer’s Disease International and World Health Organization figures). For those directly affected and their loved ones, dementia can be a frightening experience, particularly as it is so poorly understood. However there remains little or no understanding of dementia in many, and the stigmatization and misinformation that surrounds dementia remains a global issue.

For 2022 World Alzheimer’s Day the theme Know Dementia, Know Alzheimer’s, organized annually by Alzheimer’s Disease International, focuses on diagnosis, the warning signs of dementia, with a special focus on post-diagnosis support. The aim of this international campaign is to highlight the importance of support for people living with dementia and families following a diagnosis.

Biomarkers in Alzheimer's Disease, 2016, Pages 3-23

This book chapter advances SDG #3 and #10 by providing a brief outline of AD epidemiology, the definition of an AD biomarker, the classification and features of AD, and AD risk factors, followed by a description of the structure and content of each of the following chapters and their focus on specific types of AD biomarkers.

Diagnosis and Treatment of Traumatic Brain Injury, 2022, Pages 27-38

This book chapter advances SDG #3 and #10 by focusing on an emblematic delayed-onset pathology often seen after traumatic brain injury—Alzheimer’s disease—and explain its relationship with chronic traumatic encephalopathy.

Diseases of the Nervous System (Second Edition), 2021, Pages 81-107

This book chapter advances SDG #3 and #10 by introducing the basic foundation of aging, dementia and Alzheimer Disease, including clinical presentation, diagnosis and epidemiology.

Exercise to Prevent and Manage Chronic Disease Across the Lifespan, 2022, Pages 413-421

This book chapter advances SDG #3 and #10 by outlining the pathophysiology associated with Alzheimer’s disease and provide an overview of the impact of exercise programs on cognition, physical functional abilities, behavioral, and psychological symptoms and quality of life.

Genetics, Neurology, Behavior, and Diet in Dementia, The Neuroscience of Dementia, Volume 2, 2020, Pages 833-847

This book chapter advances SDG #3 and #10 by focusing on mouse models of Alzheimer’s disease (AD), especially the 5xFAD line.

Human Caspases and Neuronal Apoptosis in Neurodegenerative Diseases, 2022, Pages 69-151

This book chapter advances SDG #3 and #10 by reviewing the latest developments in the field of clinical diagnosis and pharmacotherapeutics have provided hope to ameliorate the behavioral changes and cognitive disturbances associated with the disease.

Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 223-242

This book chapter advances SDG #3 and #10 by highlighting a few newly updated nano drug delivery technologies implemented in Alzheimer’s disease therapies and prospects for the future regarding potential molecular mechanisms of nano drug delivery methods

Neurobiology of Brain Disorders (Second Edition), Biological Basis of Neurological and Psychiatric Disorders, 2022, Pages 313-336

This book chapter advances SDG #3 and #10 by reviewing several key topics that influence our understanding of pathogenic mechanisms and lead to the identification of novel therapeutic strategies. These include the diagnostic spectrum of MCI and AD, genetic risk alleles associated with late-onset AD, structures of gamma-secretase and tau, imaging and fluid biomarkers, the role of microglia and neuroinflammation, and novel animal models of AD.

Neurochemical Aspects of Alzheimer's Disease Risk Factors, Pathogenesis, Biomarkers, and Potential Treatment Strategies, 2017, Pages 47-91

This book chapter advances SDG #3 and #10 by reviewing the risk factors for Alzheimer’s Disease, including normal aging, diet, sedentary lifestyle, sleep disturbances, genes [amyloid precursor protein (APP), presenilin 1 (PSEN1), PSEN2, and APOE], environmental factors, and epigenetic factors.

Plant Extracts in Neurodegenerative Diseases, 2022, Pages 1-15

This book chapter advances SDG #3 and #10 by focusing on polyphenols and flavonoids and their crucial role in decreasing AD symptoms. In addition, it highlights the neuroprotective role of various essential ingredients of plant extracts such as Icariside, Onjisaponin B, Asarones, Liquiritin, Tanshinone IIA (TIIA) and cryptotanshinone (CT), Ginsenoside Rg1, and n-Butylidenephthalide. The efficacy of green nanotechnology are also discussed.

Pages